Conversion to microemulsion cyclosporine in stable renal transplant patients: Results after one year

Clinical Nephrology

Volumn 45, Issue 5, 1996, Pages 326-331

  Neumayer, H H ^a   Budde, K ^a   Farber L ^b   Haller, P ^c   Kohnen, R ^d   Maibucher A ^b   Schuster, A ^b   Vollmar, J ^c   Waiser, J ^a   Luft, F C ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Sandoz Corporation   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d Imerem Company   (Germany)

^e FRANZ VOLHARD CLINIC   (Germany)

Author keywords

Cyclosporine as microemulsion; Nephrotoxicity; Rejection episodes; Renal transplantation

Indexed keywords

CREATININE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LIVER ENZYME; URIC ACID;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION;

EID: 9344232747     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bach JF, Feutren G, Noel LH, Hannedouche T, Landais P, Timsit J, Boitard Ch, Bougneres P, Boitard C, Grunfeld JP, Assan R 1990 Factors predictive of cyclosporine-induced nephrotoxicity: The role of cyclosporine blood levels. Transplant Proc 22: 1296-1298
2. Brockmoöller J, Neumayer HH, Wagner K, Weber W, Hememeyer G, Kewitz H, Roots I 1990 Pharmacokinetic interaction between cyclosporine and diltiazem. Eur J Clin Pharmacol 38: 237-242
3. Burke JF, Pirsch JD, Ramos E, Salomon DR, Stublein DM, Van Buren DH, West JC 1994 Long-term efficacy and safety of cyclosporine in renat-transplant recipients. New Engl J Med 331: 358-363
4. Cockgroft DW, Gault MH 1976 Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41
5. Fahr A 1993 Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 24: 472-495
6. Ferrea G, Fioredda F, Lay A, Mangravati S, Rossi G, Basetti D 1994 Oral microemulsion formulation substitutes for intravenous cyclosporin in child with graft-versus-host disease. Lancet 344: 480-481
7. Grevel J, Napoli KL, Kahan BD 1990 Covariables in cyclosporine immunosuppression. Transplant Proc 22: 1113-1115
8. Gupta SK, Manfro RC, Tomlanovich SJ, Gambertoglio JG, Garovoy MR, Benet LZ 1990 Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J Clin Pharmacol 30: 643-653
9. Kasiske BL, Heim-Duthow K, Rao KV, Awni WM 1988 The relationship between cyclosporine pharmacokinetics and rejection in renal transplant recipients. Transplantation 46: 716-722
10. Kahan BD 1989 Cyclosporine New Engl J Med 321: 1725-1738
11. Kohnen R, Welzel D, Drechsler S Measuring quality of life with Welzel's color scale in cancer patients. Life Quality, submitted 1994
12. Korvarik JM, Mueller EA, van Bree JB, Tetzloff W, Kutz K 1994 Reduced inter- and intra-individual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharmaceutical Sciences 83: 444-449
13. Kunzendorf U, Brockmöller J, Jochimsen F, Keller F, Neumayer HH, Reisinger M, Roots I, Offermann G 1990 Pharmakokinetik von Cyclosporin und seinen Metaboliten nach Nierentransplantation. Nieren- und Hochdruckkrankheiten 10: 500-504
14. Lemaire M, Fahr A, Maurer G 1990 Pharmacokinetics of cyclosporine: Inter- and intraindividual variations and metabolic pathways. Transplant Proc 22: 1110-1112
15. Lindholm A, Henricsson S, Lind M, Dahlqvist R 1988 Intraindividual variability in the relative systemic availability of cyclosporine after oral dosing. Eur J Clin Pharmacol 34: 461-464
16. Lindholm A, Dahlqvist R, Groth GG, Sjöqvist F 1990 A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation. Br J Clin Pharmac 30: 443-452
17. Lindholm A, Dahlqvist R, Groth GG, Sjiqvist F 1990 A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation. Br J Clin Pharmacol 30: 443-402
18. Meyer MM, Munar M, Udeaja J, Bennett W 1993 Efficacy of area unter the curve cyclosporine monitoring in renal transplantation J Am Soc Nephrol 4: 1306-1315
19. Neumayer HH, Luft FC, and the Transplantationsgruppe Mittelfranken 1993 Twenty five years of renal transplantation from a single center: a risk factor analysis for short- and long-term outcomes. Clin Investig (Klin Wochenschr) 71: 341-350
20. Neumayer HH, Färber L, Haller P, Kohnen R, Maibücher A, Schuster A, Vollmar J, Waiser J 1994 Conversion from Sandimmun to Sandimmun Neoral in patients with stable renal allografts: Results after one month. Transplant Proc 5: 2944-2948
21. Neumayer HH, Färber L, Haller P, Kohnen R, Maibücher A, Schuster A, Vollmar J, Waiser J 1995 Clinical experience transferring kidney transplant patients from Sandimmun to Sandimmun Neoral - results after 3 months Clin Nephrol 43 (Suppl 1): S27-S32
22. Trull AK, Tan KKC, Uttidge J, Bauer T, Alexander GJM, Jamieson NV 1993 Cyclosporin absorption from microemulsion formulation in liver transplant recipient. Lancet 341. 433-437
23. Wagner K, Philipp T, Heinemeyer G, Brockmöller J, Roots I, Neumayer HH 1989 Interaction of cyclosporin-A and calcium antagonists. Transplant Proc 21: 1453-1456
24. Yee GC, McGuire TR 1990 Pharmacokinetic drug interactions with cyclosponne (part II). Clin Pharmacokinet 19: 400-415